FCMI
PCVX icon

Foresite Capital Management IV’s Vaxcyte PCVX Stock Holding History

Foresite Capital Management IV’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-465,821
Closed -$12.4M – 15
2020
Q4 		$12.4M Hold
465,821
– – 1.34% 10
2020
Q3 		$23M Sell
465,821
-155,000
-25% -$6.17M 5.19% 8
2020
Q2 		$19.6M Buy
+620,821
New +$20M 9.56% 5

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Foresite Capital Management IV's PCVX Position: Q1 2021 in Review

Foresite Capital Management IV sold out of Vaxcyte (PCVX) in Q1 2021, closing a stake of 465,821 shares — an estimated $12.4M sold.

Foresite Capital Management IV first reported a position in PCVX in Q2 2020 and held it in 3 quarters. The position peaked at $23M in Q3 2020. 74 funds tracked by Wall St. Rank hold PCVX as of Q1 2021.

  • Foresite Capital Management IV reported no remaining Vaxcyte position as of Q1 2021 after selling out during the quarter.
  • Foresite Capital Management IV sold 465,821 Vaxcyte shares in Q1 2021, an estimated $12.4M.
  • Foresite Capital Management IV first reported a position in Vaxcyte in Q2 2020 and held it in 3 quarters.
  • Foresite Capital Management IV's Vaxcyte position peaked at $23M in Q3 2020.
  • 74 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2021.

Based on Foresite Capital Management IV's 13F filing for Q1 2021, filed 17 May 2021.